THE AFTERMATH OF THE ASTRA ZENECA CASE. 2 ASTRA ZENECA CASE IS A PART OF A WIDER PHARMA SECTOR LANDSCAPE The landscape of competition law enforcement.

Slides:



Advertisements
Similar presentations
GREETINGS TO CHARTERED ACCOUNTANTS FOR ICAIS POST QUALIFICATION COURSE VIDEO CONFERENCE FROM HYDERABAD 26 AUGUST 2005.
Advertisements

1 ELİG Attorneys at Law ICN Plenary V: Case resolution methods and factors for effectively choosing them Gönenç Gürkaynak, LL.M., Esq.
The European Commission and national gambling monopolies European Legal Update, October 5th 2006 Thibault Verbiest Attorney at law ULYS law firm.
Patent settlements in the EU EGA perspective Ingrid Vandenborre 18 October 2013.
European legal update IGCE, November 5th 2006, Dublin Evelyn Heffermehl ULYS law firm.
The fundamentals of EC competition law
Monti II Regulation and Enforcement Directive on Posting of Workers CBSP Committee 7 November 2012 Jorma Rusanen.
André Piérard, ERGEG Project Leader on Complaints Citizens’ Energy Forum, London, September 2009 Draft advice on Customer Complaint Handling, Reporting.
“Using Competition Law to Promote Access to Health Technologies” Access to Innovation: Making Generic Versions of Newer ARVs Affordable 24 July 2014 Melbourne,
1 Challenges in Promoting Competition in the Drug Industry: The Brazilian Experience Mariana Tavares de Araujo.
XBRL AND BANKING SUPERVISION José María Roldán Director General of Regulation, Banco de España Chair, XBRL España Chair, Committee of European Banking.
International roaming Pál Belényesi University of Verona November 2006.
C OMPETITION LAW IN NIGERIA Daniel Bwala. Background There is no specific Competition law in Nigeria at the moment. However there are laws or rules in.
Waterways Forward Partnership Agreement Delft, 12 February 2010 Kick-off meeting.
Linking Intellectual Property Rights to Drug Registration: Practices and Experiences Jose Maria A. Ochave, Esq. Philippine Judicial Academy Seminar on.
Development of Competition Enforcement in Poland – 2009 Commitment Decisions Morvan Le Berre Competition Enforcement in.
Association of Pharmaceutical Companies Representatives in Georgia APCRG, WASHINGTON DC, February
© 2008 Innovate Legal Services Limited Stewards’ Inquiry? The European Commission's Investigation into Generic Entry in the Pharma Sector Dr Duncan Curley.
Rowan Freeland July 2009 The Pharma Sector Enquiry: Does it change things?
H I R S C H & P A R T N E R S A v o c a t S o l i c i t o r R e c h t s a n w a l t Pharmaceutical settlement agreements and competition law A litigation.
STRUCTURE AND FUNCTIONS OF COMPETITION AGENCIES. GENERAL STRUCTURE OF CA CAs differ in size, structure and complexity The structure depicts power distribution.
Animal Welfare EU Strategy Introduction Community Action Plan The Commission's commitment to EU citizens, stakeholders, the EP and.
The Pharmaceutical Sector Inquiry: much ado about nothing? “The facts outlined in the report are deep basic truths about this industry… there is nothing.
The ECJ's Huawei/ZTE judgment (C-170/13) Thomas Kramler DG Competition, European Commission (The views expressed are not necessarily those of the European.
The 3rd package for the internal energy market Key proposals EUROPEAN COMMISSION Heinz Hilbrecht Directorate C - Security of supply and energy markets.
ENFORCEMENT OF PATENT RIGHTS IN EUROPE The Hungarian way Zsolt SZENTPÉTERI S.B.G.&K. Patent and Law Offices, Budapest International Seminar Intellectual.
Benoît ESNAULT Commission de Régulation de l’Energie 17th Madrid Forum Madrid, 15 January year network development plan ERGEG recommendations.
International Cooperation and Capacity Building on Competition: A Swiss Perspective 7up2 Project Final Meeting Bangkok, June 28, 2006 Dr. Patrick Krauskopf.
Communication Paper on Smart Regulation COM(2010) 543, 8 October 2010 Presentation by Savia Orphanidou 3 rd November 2010.
1 Self-Regulation in the EU Advertising Sector: A Best practice model.
© 2008 Dechert LLP Pharma v. Pharma or Pharma & Pharma: The Legal Interface Between the Makers of Original and Copied Versions of Medicines AIPLA Antitrust,
Trade Defense Instruments in the EurAsEC Customs Union Andrey Zakharov Department for Internal Market Defense Eurasian Economic Commission Brussels - July.
INTRODUCTION TO THE INTERNATIONAL LABOUR STANDARDS (ILS) SYSTEM Trade Union Training on Occupational Safety, health and the Environment, with Special Attention.
International Cooperation in Cartel Investigations Regional Cooperation Hanna Witt Head of Cartel Enforcement, Swedish Competition Authority 2013 ICN Cartel.
The Pharma Sector: IP Rights and Competition Policy Ninette Dodoo Clifford Chance LLP UOHS Conference, 11 November 2009.
Living in an area of freedom, security and justice European CommissionDirectorate-General Justice and Home affairs.
Medicines and the Poor: What Role for Competition Law & Policy? Mariana Tavares de Araujo Competition Department, Head SDE, Ministry of Justice, Brazil.
1 PRESENTATION TO THE TRADE SEMINAR OF THE PORTFOLIO COMMITTEE ON TRADE AND INDUSTRY 25 AUGUST 2009 BY Siyabulela Tsengiwe: Chief Commissioner.
BETTER REGULATION STAKEHOLDERS FORUM Overview of developments in Better Regulation November 2012 Presentation by Martin Graham, DETI.
1 SG C Regulatory Fitness and Performance Programme (REFIT) Meeting of Business Statistics Directors Group Presentation by Jonathon Stoodley, Secretariat-General,
ACHIEVING A COMPETITIVE EUROPEAN GAS MARKET GIE annual conference Athens 3-4 November 2005 Maria Rehbinder EUROPEAN COMMISSION DG COMPETITION All views.
ERGEG Customers’ Focus Group Helsinki, October 2005 Chrissa Argyriou EUROPEAN COMMISSION DG Energy and Transport.
European Commission, DG Competition, A, A-4 ECN The ECN, coherency and the review of decisions of the Commission and the National Competition Authorities.
CONFERENCE IMPLEMENTATION OF MARKETS IN FINANCIAL INSTRUMENTS DIRECTIVE -MiFID- Split, June 2007 OPENING SPEECH Ante Samodol President of the Board.
Update on ECSDA Activities San Salvador March 2006 European Central Securities Depositories Association ECSDA.
The association between European Medicines Agency approval and Health Technology Assessment recommendations Iga Lipska 1,2, Anke Hövels 2, Neil McAuslane.
Competition Law and Pharma Patents Protecting your patent portfolio September 28, 2015 Tine Van den Haute EU Competition law counsel, Merck Sharp & Dohme.
REPUBLIC OF ALBANIA PUBLIC PROCUREMENT AGENCY Eighth Regional Public Procurement Forum May, 22-25, 2012 Tirana
Patent settlements for medicines -- status under EU and US antitrust law -- Luc Gyselen, Partner Arnold & Porter LLP Brussels Symposium on the Interface.
Recent FTC Pharmaceutical Cases: Background and Examples Sue H. Kim This presentation was prepared from public sources. The views expressed herein do not.
1 EFPIA’s Response to The Pharmaceutical Sector Inquiry Preliminary Report Brian Healy, Ph. D Merck & Co Member of EFPIA Sector Inquiry Task Force.
Prof. Frederick Abbott UNDP Consultant
The EU International Procurement Instrument - in the Age of Economic Nationalism Rome, 4 July 2017 Dr. Aris GEORGOPOULOS University of Nottingham, School.
A New Settlement for the UK within the EU
EU Sanctions on Individuals
The JFTC’s ICN Work Products implementation
Competition Law and its Application: European Union
The 3rd package for the internal energy market
ENFORCEMENT OF PATENT RIGHTS IN EUROPE The Hungarian way
Interactive Gaming Council Board Meeting I-Gaming Legal status
Lesson Objectives All students will understand the importance of regulation in some markets Most students will be able to assess the why the regulation.
LIDC Prague, 12 October 2012 EU competition law and end-of-lifecycle pharmaceutical products Blaž Višnar DG Competition DISCLAIMER “The views expressed.
Competition Law Enforcement in the E.U. - Dawn Raids -
INTRODUCTION TO GDPR 19/09/2018.
Nikolai Khaltaev GARD Meeting ERS Congress 3 September, Munich
Professional experience
The interaction between public and private enforcement of EU competition rules Helena Penovski European Competition Network and Private Enforcement Unit.
LIDC Prague, 12 October 2012 EU competition law and end-of-lifecycle pharmaceutical products Blaž Višnar DG Competition DISCLAIMER “The views expressed.
Animal Welfare EU Strategy
WG Environmental Expenditure Statistics Green public procurement (GPP)
Presentation transcript:

THE AFTERMATH OF THE ASTRA ZENECA CASE

2 ASTRA ZENECA CASE IS A PART OF A WIDER PHARMA SECTOR LANDSCAPE The landscape of competition law enforcement in the EU in the Pharmaceutical Sector consists of: -the Astra Zeneca decision; -the Pharmaceutical Sector Inquiry; -the Preliminary Findings after the Inquiry and the Final Report of the Inquiry in 2009; -The Aftermath of the Pharma Sector Inquiry (Laboratoires Servier, Lundbeck) -Monitoring exercises in patent settlements by the EU Commission; -National Cases (UK, Italy as significant examples)

3

4 PHARMACEUTICAL SECTOR INQUIRY – MAIN POINTS Final report published on 8 July 2009 after 18-month inquiry Contrast between early findings and final conclusions; Further scrutiny announced for three areas: Patent settlements, „defensive” patents and regulatory complaints; No frontal attack on patents

5 PHARMACEUTICAL SECTOR INQUIRY– MAIN POINTS II When generics come into the market… Patent settlements Patent portfolios Patent Settlements and „reverse payments” Complaints to regulators „Defensive Patents” Policy recommendations Further scrutiny announced for three areas: Patent settlements, „defensive” patents and regulatory complaints; No frontal attack on patents

6 PHARMACEUTICAL SECTOR INQUIRY – AFTERMATH Boehringer Ingelheim: misuse of patent system to exclude potential competition (old case); Les Laboratoires Servier: attempts to delay entry of generics; Sanofi-Aventis, Teva, Novartis, Sandoz, Ratiopharm and Ranbaxy – dawn raids in November 2009

7 PHARMACEUTICAL SECTOR INQUIRY – PATENT SETTLEMENT MONITORING EXERCISE Monitoring exercises in patent settlements by the EU Commission: - January 2010 – the Commission requests copies of patent settlement agreements; - 5 July 2010 – First Commission Report on the Monitoring of the Patent Settlements – claims reduction of „problematic settlements” - 17 January 2011 – Second Monitoring Exercise of Patent Settlements in Pharma Sector

8 NATIONAL CASES – UK AND ITALY UK OFFICE OF FAR TRADING – RECKITT BENCKISER (Gaviscon case) – October 2010 early resolution agreement – admission of infringement by selective withdrawal and de-listing from NHS prescription channel; ITALIAN COMPETITION AUTHORITY investigation – Misuse of patent – Ratiopharm/Pfizer – October 2010 alleged abuse through application for a divisional patent and subsequent request for a supplementary patent certificate (SPC)

9 CONCLUSIONS „Snowball” effect across the European Union countries; Good example of new-era competition enforcement in the EU; -policy approach at EU level -sector inquiries as an enforcement tool; -importance of commitments; -follow-UP national cases;

10

Thank you for your attention ! For any questions –